Compare RRR & PBLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RRR | PBLS |
|---|---|---|
| Founded | 1976 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Hotels/Resorts | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.9B | 3.6B |
| IPO Year | 2015 | 2026 |
| Metric | RRR | PBLS |
|---|---|---|
| Price | $64.23 | $30.01 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 13 | 0 |
| Target Price | ★ $69.69 | N/A |
| AVG Volume (30 Days) | ★ 696.6K | 545.1K |
| Earning Date | 04-29-2026 | N/A |
| Dividend Yield | ★ 3.64% | N/A |
| EPS Growth | ★ 23.32 | N/A |
| EPS | ★ 0.73 | N/A |
| Revenue | ★ $2,011,483,000.00 | N/A |
| Revenue This Year | $3.41 | N/A |
| Revenue Next Year | $4.62 | N/A |
| P/E Ratio | $88.96 | ★ N/A |
| Revenue Growth | ★ 3.74 | N/A |
| 52 Week Low | $50.52 | $25.56 |
| 52 Week High | $68.99 | $33.65 |
| Indicator | RRR | PBLS |
|---|---|---|
| Relative Strength Index (RSI) | 54.16 | 56.09 |
| Support Level | $59.81 | $26.96 |
| Resistance Level | $68.55 | $30.90 |
| Average True Range (ATR) | 1.92 | 2.47 |
| MACD | -0.28 | -0.11 |
| Stochastic Oscillator | 40.40 | 51.59 |
Red Rock Resorts Inc along with its subsidiary is a gaming, development and management company that develops and operates strategically-located casino and entertainment properties. Its casino properties are conveniently located throughout the Las Vegas valley and provide its customers a wide variety of entertainment and dining options. The majority of revenue is derived from Casinos, followed by Food and Beverages, Rooms and others.
Parabilis Medicines Inc s a clinical-stage biopharmaceutical company. It is focused on the development of medicines targeting protein interactions associated with human diseases. It uses a proprietary platform to develop stabilized helical peptide therapeutics, referred to as Helicons, designed to bind and modulate specific proteins. Its flagship product candidate, zolucatetide, targets the interaction between β-catenin and the T-cell factor (TCF) family of transcription factors within the Wnt/β-catenin signaling pathway, which is associated with cell proliferation and differentiation in multiple cancer types.